# China NMPA Drug Inspection - Anhui Jiezhong Biochemical Co., Ltd. - 6 batches of Chinese herbal medicine pieces

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/anhui-jiezhong-biochemical-co-ltd/dbbc5659-14f9-4ffe-bd0b-44c46f31fdbb/
Source feed: China

> China NMPA drug inspection for Anhui Jiezhong Biochemical Co., Ltd. published August 17, 2018. Drug: 6 batches of Chinese herbal medicine pieces. The Shandong Provincial Food and Drug Administration issued an announcement on August 17, 2018, detailing the results of

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement from Shandong Provincial Food and Drug Administration Regarding 10 Batches of Drugs Failing Quality Inspection (Issue No. 8, 2018)
- Company Name: Anhui Jiezhong Biochemical Co., Ltd.
- Publication Date: 2018-08-17
- Drug Name: 6 batches of Chinese herbal medicine pieces
- Inspection Finding: The quality of the random inspection did not meet the standard requirements.
- Action Taken: Control measures such as sealing, seizure, suspension of sales, and product recall have been taken, and cases have been filed against the relevant manufacturers and sampled units in accordance with relevant laws and regulations.
- Summary: The Shandong Provincial Food and Drug Administration issued an announcement on August 17, 2018, detailing the results of quality inspections on ten batches of drugs. Conducted by six drug testing institutions, including the Zibo Municipal Institute for Food and Drug Control, these inspections identified significant quality failures.

Specifically, four batches of drugs produced by three companies, including Yuanda Pharmaceutical Huangshi Feiyun Pharmaceutical Co., Ltd., and six batches of traditional Chinese medicine decoction pieces from five companies, including Anhui Jiezhong Biochemical Co., Ltd., did not meet established quality standards. This constituted a critical violation of regulatory requirements for drug quality in China.

In response, relevant municipal food and drug administrations implemented immediate control measures. These included sealing, seizing, suspending sales, and recalling the affected products to prevent further public exposure. Furthermore, investigations and legal proceedings have been initiated against the responsible manufacturers and distribution units, operating under the regulatory framework overseen by national and provincial medical product administrations. Enterprises are mandated to thoroughly investigate the root causes of these deficiencies, develop and execute comprehensive rectification plans, and effectively mitigate all identified risks to ensure future compliance and product safety.

Company: https://www.globalkeysolutions.net/companies/anhui-jiezhong-biochemical-co-ltd/a663a46b-9b30-4e79-90aa-2a48c6be4da9/